In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians.
Promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test.
Dr. Skibo discusses how ddPCR-based liquid biopsy could become an indispensable method for doctors to categorize a patient’s disease.
Clinical lab products article: Blood-Based Approach to PD-L1 Detection Shows Concordance with Immunohistochemistry. Comments from Dr. Pritchett, Dr. Niu
Dr. Paul Walker describes how liquid biopsy testing helps battling lung cancer in the tobacco belt. The advantages of liquid biopsy for lung cancer.
Dr. Skibo discusses how ddPCR-based liquid biopsy could be the solution to treatment delays due to receiving genetic information late.
ROS1 and RET mutations are now available in Biodesix's liquid biopsy test, GeneStrat
Genestrat: a targeted liquid biopsy for patients with NSCLC. Blood test with 72 hour turnaround time.
Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.
Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. It all comes down to a blood test called VeriStrat.